NCT/Study#

NCT03581292 /

COG-ACNS1721

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With ACTIVEly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With ACTIVEly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

DISEASE GROUP:
Pediatric Oncology
current phase:
Phase II
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: